BridgeBio Pharma (FRA:2CL) FCF Margin %: -101.46% (As of Mar. 2026)

What is BridgeBio Pharma FCF Margin %?

BridgeBio Pharma FRA:2CL +0.03% 66 FCF Margin % is -101.46% as of Mar. 2026. GuruFocus rates FRA:2CL with a GF Score™ of 66/100 and a GF Value™ of €121.36 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 960 Biotechnology companies, BridgeBio Pharma ranks better than 50.52% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. BridgeBio Pharma's Free Cash Flow for the three months ended in Mar. 2026 was €-170.7 Mil. BridgeBio Pharma's Revenue for the three months ended in Mar. 2026 was €168.3 Mil. Therefore, BridgeBio Pharma's FCF Margin % for the quarter that ended in Mar. 2026 was -101.46%.

As of today, BridgeBio Pharma's current FCF Yield % is -3.31%.

The historical rank and industry rank for BridgeBio Pharma's FCF Margin % or its related term are showing as below:

FRA:2CL' s FCF Margin % Range Over the Past 10 Years
Min: -5686.62 Med: -631.72 Max: -78.03
Current: -78.03

During the past 9 years, the highest FCF Margin % of BridgeBio Pharma was -78.03%. The lowest was -5686.62%. And the median was -631.72%.

FRA:2CL's FCF Margin % is ranked better than
50.52% of 960 companies
in the Biotechnology industry
Industry Median: -85.21 vs FRA:2CL: -78.03

BridgeBio Pharma FCF Margin % Related Terms

BridgeBio Pharma FCF Margin % Historical Data

* Premium members only.

The historical data trend for BridgeBio Pharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BridgeBio Pharma FCF Margin % Chart

BridgeBio Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

FCF Margin %

Get a 7-Day Free Trial

-783.43

-548.39

-5,686.52

-238.68

-90.72

BridgeBio Pharma Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
FCF Margin %	Get a 7-Day Free Trial															-172.19	-77.58	-93.16	-36.62	-101.46

FRA:2CL vs EXEL, IONS, SMMT: FCF Margin % Comparison

For the Biotechnology subindustry, BridgeBio Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BridgeBio Pharma FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where BridgeBio Pharma's FCF Margin % falls into.

Save Embed

66GF Score

BridgeBio Pharma Inc FRA:2CL

FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

BridgeBio Pharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

BridgeBio Pharma's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-388.999	/	428.773
	=	-90.72 %

BridgeBio Pharma's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-170.706	/	168.255
	=	-101.46 %

Frequently Asked Questions Learn more about FCF Margin % →

What does a FCF Margin % of -101.46% mean?

BridgeBio Pharma (FRA:2CL) has a FCF Margin % of -101.46% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on BridgeBio Pharma and its competitors. According to the industry distribution chart, BridgeBio Pharma ranks #475 out of 960 companies in the Biotechnology industry, placing it in the top 49.5%.

Is BridgeBio Pharma's FCF Margin % too high?

BridgeBio Pharma's current FCF Margin % is -101.46%. Based on the distribution chart, BridgeBio Pharma ranks #475 out of 960 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BridgeBio Pharma has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does BridgeBio Pharma's FCF Margin % compare to EXEL and IONS?

According to the Biotechnology industry distribution chart, BridgeBio Pharma ranks #475 out of 960 companies for FCF Margin %. This puts BridgeBio Pharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good FCF Margin % for a Biotechnology company?

A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high FCF Margin % mean?

A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on BridgeBio Pharma and its competitors. BridgeBio Pharma's current FCF Margin % is -101.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is BridgeBio Pharma stock overvalued right now?

Based on GuruFocus' analysis, BridgeBio Pharma (FRA:2CL) is currently considered Possible Value Trap. The stock's GF Value™ is €121.36, compared to a current price of €60.30 — trading 50.3% below its estimated fair value. The current FCF Margin % is -101.46%. BridgeBio Pharma's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is FCF Margin % calculated?

FCF Margin % is calculated from a company's financial statements. For BridgeBio Pharma (FRA:2CL), the current FCF Margin % is -101.46% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BridgeBio Pharma (FRA:2CL) Overvalued in 2026?

Based on GuruFocus' analysis, BridgeBio Pharma stock appears to be undervalued. The current stock price of €60.30 is trading 50.3% below its estimated GF Value™ of €121.36. GuruFocus considers BridgeBio Pharma to be Possible Value Trap.

Key valuation signals for FRA:2CL:

FCF Margin %: -101.46%
GF Value™: €121.36 vs. price of €60.30 (50.3% below fair value)
GF Score™: 66/100 with 7 warning signs

No single metric tells the full story. See the FRA:2CL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BridgeBio Pharma Business Description

Industry Healthcare Biotechnology

Comparable Companies EXEL IONS SMMT ASND AXSM MDGL JAZZ BMRN ARWR CYTK VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges BBIO:USA 1BBIO:Italy

Address 3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304

Website https://www.bridgebio.com

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

66GF Score

Get the complete analysis for FRA:2CL

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€60.30

Price

€121.36

GF Value

View FRA:2CL Analysis

See FCF Margin % data for all stocks →